Vor Biopharma (NASDAQ:VOR - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($2.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($1.61), Zacks reports.
Vor Biopharma Stock Performance
NASDAQ VOR traded down $0.33 on Tuesday, reaching $1.66. The company had a trading volume of 6,536,811 shares, compared to its average volume of 7,965,030. The company has a market cap of $210.22 million, a P/E ratio of -1.10 and a beta of 2.06. Vor Biopharma has a 12 month low of $0.13 and a 12 month high of $3.29.
Analyst Ratings Changes
Several analysts have recently commented on the stock. HC Wainwright upgraded shares of Vor Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Monday, June 30th. Wall Street Zen downgraded shares of Vor Biopharma to a "strong sell" rating in a research report on Saturday, June 28th.
Read Our Latest Report on Vor Biopharma
Vor Biopharma Company Profile
(
Get Free Report)
Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access